The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.
age 18 years or older
currently living in the United States
have access to the internet and a computer, laptop, tablet or smartphone
willing to provide written informed consent for participation
Not able to meet or fulfill any of the inclusion criteria
The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.
Case-control
Cross-sectional
Not listed
Genetic risk variants associated with blood cancer
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.
Click on the lead sponsor to view all of their trials.
Rutgers, The State University of New Jersey
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
